CDX-110

Known as: CDX 110, CDX110 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
BACKGROUND Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary… (More)
Is this relevant?
2015
2015
G lioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Standard therapy, including maximal surgical… (More)
Is this relevant?
2011
2011
TO THE EDITOR: Sampson et al are to be congratulated for their paper on the use of the epidermal growth factor receptor variant… (More)
Is this relevant?
2009
2009
2021 Background: Unlike conventional therapies for GBM, immunologic targeting of tumor-specific gene mutations allows precise… (More)
Is this relevant?
Review
2009
Review
2009
Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, resulting in non-specific… (More)
Is this relevant?